Free Trial

Genprex (GNPX) Competitors

Genprex logo
$0.26 -0.01 (-4.07%)
As of 09:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GNPX vs. CARA, TENX, LSTA, CYTH, FBLG, KLTO, NNVC, BCAB, SNYR, and CMMB

Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), NanoViricides (NNVC), BioAtla (BCAB), Synergy CHC (SNYR), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

Genprex vs. Its Competitors

GENPREX (NASDAQ:GNPX) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, GENPREX's average media sentiment score of 0.00 equaled Cara Therapeutics'average media sentiment score.

Company Overall Sentiment
GENPREX Neutral
Cara Therapeutics Neutral

GENPREX has higher earnings, but lower revenue than Cara Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GENPREXN/AN/A-$21.11MN/AN/A
Cara Therapeutics$7.14M0.00-$118.51M-$21.01N/A

14.1% of GENPREX shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 8.5% of GENPREX shares are owned by insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GENPREX has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Cara Therapeutics' return on equity of -367.97% beat GENPREX's return on equity.

Company Net Margins Return on Equity Return on Assets
GENPREXN/A -664.65% -370.18%
Cara Therapeutics -1,099.76%-367.97%-107.43%

GENPREX has a beta of -0.5, suggesting that its stock price is 150% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Summary

Cara Therapeutics beats GENPREX on 5 of the 8 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNPX vs. The Competition

MetricGENPREXMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.32M$2.89B$5.53B$9.02B
Dividend YieldN/A2.44%5.22%3.99%
P/E RatioN/A21.7127.8120.25
Price / SalesN/A283.26429.10119.26
Price / CashN/A41.7026.2128.59
Price / Book1.757.538.025.65
Net Income-$21.11M-$55.14M$3.18B$249.15M
7 Day Performance15.40%4.22%2.88%2.91%
1 Month Performance-8.55%0.91%1.66%4.11%
1 Year Performance-86.16%5.40%34.25%20.98%

Genprex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNPX
Genprex
1.0451 of 5 stars
$0.26
-4.1%
N/A-86.2%$7.32MN/A0.0020Gap Down
CARA
Cara Therapeutics
0.3386 of 5 stars
N/AN/AN/A$24.33M$7.14M-0.2580Gap Down
High Trading Volume
TENX
Tenax Therapeutics
1.2656 of 5 stars
$5.76
-1.5%
$17.50
+203.8%
+88.0%$24.27MN/A-2.329
LSTA
Lisata Therapeutics
2.4915 of 5 stars
$2.90
+3.6%
$15.00
+417.2%
-24.8%$24.12M$1M-1.2630Positive News
CYTH
Cyclo Therapeutics
N/A$0.72
flat
$0.95
+31.8%
N/A$23.72M$870.73K-0.809
FBLG
FibroBiologics
2.5375 of 5 stars
$0.62
+0.7%
$13.00
+1,989.4%
-87.0%$23.65MN/A0.0010Gap Up
KLTO
Klotho Neurosciences
N/A$1.13
+56.9%
N/AN/A$23.40MN/A0.00N/AAnalyst Upgrade
High Trading Volume
NNVC
NanoViricides
1.0972 of 5 stars
$1.40
flat
N/A-20.0%$22.50MN/A-1.9420News Coverage
Gap Down
BCAB
BioAtla
2.7307 of 5 stars
$0.40
+3.1%
$5.00
+1,162.6%
-71.2%$22.43M$11M-0.3260Gap Down
SNYR
Synergy CHC
3.757 of 5 stars
$2.85
+17.3%
$10.00
+250.9%
N/A$22.34M$34.83M0.0040High Trading Volume
CMMB
Chemomab Therapeutics
2.8921 of 5 stars
$1.16
-0.9%
$8.50
+632.8%
+19.8%$22.06MN/A-1.5320Gap Up

Related Companies and Tools


This page (NASDAQ:GNPX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners